Cresset Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cresset Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-300	Closed	-$121K	–	1869
2024 Q4	$121K	Hold	300	–	–	﹤0.01%	1617
2024 Q3	$140K	Sell	300 -1,800	-86%	-$865K	﹤0.01%	2011
2024 Q2	$984K	Sell	2,100 -4,000	-66%	-$1.74M	﹤0.01%	1076
2024 Q1	$2.55M	Buy	+6,100	New	+$2.58M	0.01%	543
2023 Q4	–	Sell	-133,200	Closed	-$46.3M	–	1925
2023 Q3	$46.3M	Buy	+133,200	New	+$46.6M	0.18%	63

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Cresset Asset Management's VRTX Position: Q1 2026 in Review

Cresset Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 4% in Q1 2026, buying an estimated $142K and bringing the position to 7,860 shares worth $3.51M. The position accounts for 0.02% of the portfolio, ranked #442.

Cresset Asset Management first reported a position in VRTX in Q4 2018 and has held it in 28 quarters since. The position peaked at $11.2M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Cresset Asset Management held 7,860 shares of Vertex Pharmaceuticals worth $3.51M as of Q1 2026.
Cresset Asset Management bought 305 Vertex Pharmaceuticals shares in Q1 2026, an estimated $142K.
Vertex Pharmaceuticals made up 0.02% of Cresset Asset Management's portfolio in Q1 2026, its #442 holding.
Cresset Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 28 quarters since.
Cresset Asset Management's Vertex Pharmaceuticals position peaked at $11.2M in Q3 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.